FOLH1 and prostate cancer: Our observations are in accordance with the study of Dietlein et al. who reported detection of prostate cancer lesions by [89Zr]Zr-PSMA-DFO PET/CT (at 2–3 days p.i.)in 8/14 (57%) patients with initially negative PSMA-targeted PET/CT ([68Ga]Ga-PSMA-11 or [18F]-JK-PSMA-7) [33].